PTCT

#2359
PTC Therapeutics, Inc. - Common Stock
73.8 5 USD
+3.94%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
73.85
73.85
Rango anual
44.17
87.50
Cambio diario
+3.94%
Variación mensual
+13.98%
Variación en los últimos 6 meses
-11.23%
Cambio anual
+50.99%
Cierres anteriores
71.0 5
Open
73.8 5
Mínimo
73.8 5
High
73.8 5
Volumen
158
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 612.58 M
  • Employee 991
  • Founded 1998
  • CEO Matthew B. Klein
  • Website www.ptcbio.com
  • Headquarter Delaware, United States
  • FIGI BBG000QT15P7
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
9.76
Relación precio/flujo de caja
3.88

PTC Therapeutics, Inc. - Common Stock

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.

Noticias